| Project/Area Number |
17K17636
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Laboratory animal science
Experimental pathology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
Kanda Masato 千葉大学, 大学院医学研究院, 助教 (50444055)
|
|---|
| Project Period (FY) |
2017-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 心筋再生 / 細胞移植療法 / 心筋梗塞 / 褐色脂肪組織細胞 / 細胞移植治療 / 褐色細胞組織 / 褐色脂肪組織 / 再生促進因子 |
|---|
| Outline of Final Research Achievements |
The purpose of this study was to develop a new cell transplantation therapy for myocardial infarction, and to develop a mouse model that can detect the site of myocardial regeneration by the therapy, thereby establishing a method for the search for novel regeneration-promoting factors. Using a myocardial-specific multi-fluorescent mouse model (Rainbow-Cre mouse), we confirmed that the frequency of regeneration increased in the peri-infarct region by clonal proliferation of fluorescent myocardium in the chronic phase after myocardial infarction. Then, we developed a transplantation therapy of brown adipose tissue (BAT) cells with enhanced viability by biomaterials, and were able to confirm the trend of suppressing cardiac remodeling and preserving cardiac function. This has allowed us to establish a new transplantation therapy for myocardial infarction and a technique to specifically capture the site of accelerated proliferation at the time of cell transplantation.
|
| Academic Significance and Societal Importance of the Research Achievements |
心臓移植以外に根本的な治療法は見つかっていない慢性心筋梗塞およびそれに伴う心不全に対して、心機能を回復させる根本的治療としての再生医療の開発を目指し、拒絶反応が起こりにくい、細胞定着率の高い新しい手法を確立することができた。そして、移植治療に伴う、残存心筋由来の心筋再生頻度を正確に評価でき、増殖部位からのサンプル採取が可能なモデルを開発できたことで、新規再生促進物質を探索し、新規治療の開発につながっていくことが期待される。
|
